ZeptoMetrix News
- Showing 1–14 of 14 items
We are committed to producing high-quality molecular controls which can help you provide accurate and reliable test results.
Is this "Tripledemic" keeping you up at night? We have developed the broadest line of respiratory and coronavirus controls and panels to help you confidently monitor the continued performance of your multiplexed assays.
ZeptoMetrix® has successfully completed its first EU Quality Management System Audit from British Standards Institution BSI, NB 2797, one of the notified bodies under the new In Vitro Diagnostics Regulation (IVDR).
Microneutralization end point–dilution assays were performed at ZeptoMetrix. SARS-CoV-2 virus, isolate USA-WA1/2020, NR-52281 (CDC and BEI Resources, National Institute of Allergy and Infectious Diseases, NIH) was used for microneutralization end point–dilution assays.
New ZeptoMetrix® NATtrol™ SARS-CoV-2 Omicron Control Now Available
ZeptoMetrix® launches the SARS-CoV-2 Omicron Control. Now available for pre-order.
ZeptoMetrix® Launches New Ready-to-Use SARS-CoV-2 Delta Variant Molecular Quality Controls.
Rheonix utilizes ZeptoMetrix reagents to advance rapid diagnostic COVID-19 testing.
This podcast series highlights career insights from pharmaceuticals and health science experts.
ZeptoMetrix® supports NovaSterilis in achieving EUA for the Nova2020™ system in decontaminating select N95 respirators.
FDA suggests ZeptoMetrix® test materials for SARS-CoV-2 assay validation.
ZeptoMetrix® and the University of Buffalo are leveraging resources to develop new quality control products for infectious disease diagnostics.
ZeptoMetrix® newly inactivated and non-infectious NATtrol™ SARS-CoV-2 Recombinant is available for sale
IDbyDNA Announces Agreement with ZeptoMetrix to Support Quality Control Products.